reports
- Maxim Jacobs
CollPlant Holdings - Big potential for BioInk
Over the course of H217, CollPlant announced that it had received orders for its BioInk product from two companies for development of 3D printed organs and orthopaedic devices respectively. In the FY17 results the company announced that the first two orders accounted for NIS0.69m in revenue, bringing revenue for the year to NIS1.67m. One of the clients placed a repeat order, which is expected to be recorded in Q118 results.
- Maxim Jacobs
CollPlant Holdings - Steady commercial advancement
CollPlant’s Q317 marked continued commercial progress and increasing interest in its plant-based recombinant human collagen (rhCollagen) based technology. It announced multiple sales of its bioInk product for 3D tissue printing to a major biotechnology company and a major medical device company, which is very encouraging and potentially validating. Additionally, it expanded its commercial footprint for VergenixFG to Greece and Cyprus with a new distribution deal.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.